Details for Patent: 7,811,595

Which drugs does patent 7,811,595 protect, and when does it expire?

Patent 7,811,595 protects VAFSEO and is included in one NDA.

This patent has forty-eight patent family members in twenty-five countries.

Summary for Patent: 7,811,595

Title:	Prolyl hydroxylase inhibitors and methods of use
Abstract:	The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Inventor(s):	Richard Masaru Kawamoto, Shengde Wu, Namal C. Warshakoon, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer
Assignee:	Akebia Therapeutics Inc
Application Number:	US11/821,936
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,811,595
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 7,811,595

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-001	Mar 27, 2024		RX	Yes	No			Y	Y
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-002	Mar 27, 2024		RX	Yes	No			Y	Y
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes			Y	Y

International Family Members for US Patent 7,811,595

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E485264
Australia	2007265460
Brazil	PI0713350